Synergism of PDL/PD1 and IL33/ST2 Axis in Tumor Immunology

Marina Jovanovic; Nevena Gajovic; Miodrag L. Lukic; Ana Popovic; Ivan Jovanovic

doi:10.2478/sjecr-2018-0033

.blurhash-client-img { display: none !important; }

Synergism of PDL/PD1 and IL33/ST2 Axis in Tumor Immunology

EABR. Experimental and Applied Biomedical Research

Volume 20 (2019): Issue 3 (September 2019)

By: Marina Jovanovic, Nevena Gajovic, Miodrag L. Lukic, Ana Popovic and Ivan Jovanovic

Open Access

|Nov 2019

Abstract

When it comes to tumor immunology, understanding of molecular pathways is rather important. During oncogenesis, many molecules should be taken in consideration altogether in context of a single malignancy. It is of a great significance to determine whether these molecules act synergistically or contrary, whether to understand a malignant disease more thoroughly, or even more important, to reveal new approaches of therapy. In this review, we discuss whether and how IL-33/ST2 and PD-1/PDL axis involve in antitumor immunity.

References

1. Garlanda C, Dinarello CA, Mantovani A. The interleukin – 1 family: back to the future. Immunity. 2013;39(6):1003-1018.10.1016/j.immuni.2013.11.010393395124332029
Open DOI Search in Google Scholar Back to article
2. Günther S et al. IL-1 Family Cytokines Use Distinct Molecular Mechanisms to Signal through Their Shared Co-receptor. Immunity. 2017 19;47(3):510-52310.1016/j.immuni.2017.08.004584908528930661
Search in Google Scholar Back to article
3. Wasmer M-H, Krebs P. The Role of IL-33-Dependent Inflammation in the Tumor Microenvironment. Frontiers in Immunology. 2016;7:682.10.3389/fimmu.2016.00682
Search in Google Scholar Back to article
4. Ali S, Mohs A, Thomas M, Klare J, Ross R, Schmitz ML, Martin MU. The dual function cytokine IL-33 interacts with the transcription factor NF-κB to dampen NF-κB-stimulated gene transcription. J Immunol. 2011;15;187(4):1609-16.10.4049/jimmunol.100308021734074
Search in Google Scholar Back to article
5. Gadina M, Jefferies CA. IL-33: a sheep in wolf’s clothing? Sci STKE. 2007 Jun 12;2007:390.10.1126/stke.3902007pe3117565120
Search in Google Scholar Back to article
6. Gao X et al. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. J Immunol. 2015 Jan 1;194(1):438-4510.4049/jimmunol.1401344427290125429071
Search in Google Scholar Back to article
7. Lu B, Yang M, Wang Q. Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy. J Mol Med; 2016;94(5):535-432692261810.1007/s00109-016-1397-026922618
Open DOI Search in Google Scholar Back to article
8. Dominguez D et al. Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer. Immunol. 2017 1;198(3):1365-137510.4049/jimmunol.1501399526311328011934
Search in Google Scholar Back to article
9. Amôr NG et al. ST2/IL-33 signaling promotes malignant development of experimental squamous cell carcinoma by decreasing NK cells cytotoxicity and modulating the intratumoral cell infiltrate. Oncotarget. 2018 Jul 20;9(56):30894-30904.10.18632/oncotarget.25768608939930112116
Search in Google Scholar Back to article
10. Lin SH et al. Inflammation elevated IL-33 originating from the lung mediates inflammation in acute lung injury. Clin Immunol; 2016; 30535-6.10.1016/j.clim.2016.10.01427989898
Search in Google Scholar Back to article
11. Yang M, Feng Y, Yue C, Xu B, Chen L, Jiang J, Lu B, Zhu Y. Lower expression level of IL-33 is associated with poor prognosis of pulmonary adenocarcinoma. PLoS One. 2018 2;13(3).10.1371/journal.pone.0193428583417529499051
Search in Google Scholar Back to article
12. Chen J et al. Interleukin-33 Contributes to the Induction of Th9 Cells and Antitumor Efficacy by Dectin-1-Activated Dendritic Cells. Front Immunol. 2018 31;9:1787.10.3389/fimmu.2018.01787607924230108595
Search in Google Scholar Back to article
13. Jovanovic I, Radosavljevic G, Mitrovic M, Juranic VL, McKenzie AN, Arsenijevic N, et al. (2011) ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma. Eur J Immunol 41: 1902–1912.10.1002/eji.201141417374612721484786
Open DOI Search in Google Scholar Back to article
14. Zhang Y et al. IL-33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis. Mol Carcinog 56: 272–287.10.1002/mc.22491563013627120577
Search in Google Scholar Back to article
15. Ishikawa K et al. Expression of interleukin-33 is correlated with poor prognosis of patients with squamous cell carcinoma of the tongue. Auris Nasus Larynx. 2014 Dec;41(6):552-7.10.1016/j.anl.2014.08.00725193287
Open DOI Search in Google Scholar Back to article
16. Chen SF et al. The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol. 2013 Oct;231(2):180-9.10.1002/path.422623775566
Search in Google Scholar Back to article
17. Lu B, Yang M, Wang Q. Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy. J Mol Med 94: 535–543.10.1007/s00109-016-1397-026922618
Search in Google Scholar Back to article
18. Li J et al. Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest. 2014; 124(7):3241-51.10.1172/JCI73742407137024892809
Search in Google Scholar Back to article
19. Zhang JF et al. IL33 enhances glioma cell migration and invasion by upregulation of MMP2 and MMP9 via the ST2-NF-κB pathway. Oncol Rep. 2017 Oct;38(4):2033-2042.10.3892/or.2017.5926565295128849217
Open DOI Search in Google Scholar Back to article
20. Xiao P et al. Interleukin 33 in tumor microenvironment is crucial for the accumulation and function of myeloid-derived suppressor cells. Oncoimmunology. 2015. 24;5(1)10.1080/2162402X.2015.1063772476033826942079
Search in Google Scholar Back to article
21. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBOJ. 1992 (11):3887-9510.1002/j.1460-2075.1992.tb05481.x
Search in Google Scholar Back to article
22. Park YJ, Kuen DS, Chung Y. Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance. Exp Mol Med. 2018 22;50(8):109.10.1038/s12276-018-0130-1610567430135516
Search in Google Scholar Back to article
23. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010; 236: 219-242.10.1111/j.1600-065X.2010.00923.x291927520636820
Search in Google Scholar Back to article
24. Ortler S et al. B7-H1 restricts neuroantigen-specific T cell responses and confines inflammatory CNS damage: implications for the lesion pathogenesis of multiple sclerosis. Eur J Immunol. 2008;38(6):1734-4410.1002/eji.20073807118421793
Search in Google Scholar Back to article
25. Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18(3):153-16710.1038/nri.2017.10828990585
Search in Google Scholar Back to article
26. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008; 8: 467-477.10.1038/nri232618500231
Search in Google Scholar Back to article
27. Gupta PK et al. CD39 Expression Identifies Terminally Exhausted CD8+ T Cells. PLoS Pathog. 2015;11(10):e1005177.10.1371/journal.ppat.1005177461899926485519
Search in Google Scholar Back to article
28. Starr R et al. A family of cytokine-inducible inhibitors of signalling. Nature. 1997; 387: 917-921.10.1038/432069202125
Search in Google Scholar Back to article
29. Massari F et al. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. Cancer Treat Rev. 2015; 41: 114-121.10.1016/j.ctrv.2014.12.01325586601
Search in Google Scholar Back to article
30. Ahmad SM et al. The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy. Oncoimmunology. 2017;7(2): e1390641.10.1080/2162402X.2017.1390641574966929308318
Search in Google Scholar Back to article
31. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219-42.10.1111/j.1600-065X.2010.00923.x
Search in Google Scholar Back to article
32. Reynolds J et al. Stimulation of the PD-1/PDL-1 T-cell co-inhibitory pathway is effective in treatment of experimental autoimmune glomerulonephritis. Nephrol Dial Transplant. 2012 Apr;27(4):1343-50.10.1093/ndt/gfr52921965585
Search in Google Scholar Back to article
33. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26:677–704.10.1146/annurev.immunol.26.021607.09033118173375
Search in Google Scholar Back to article
34. White MPJ, Webster G, Leonard F, La Flamme AC. Innate IFN-γ ameliorates experimental autoimmune encephalomyelitis and promotes myeloid expansion and PDL-1 expression. Sci Rep. 2018 Jan 10;8(1):259.10.1038/s41598-017-18543-z576289129321652
Search in Google Scholar Back to article
35. Rowe JH, Ertelt JM, Way SS. Innate IFN-γ is essential for programmed death ligand-1-mediated T cell stimulation following Listeria monocytogenes infection. J Immunol. 2012;189(2):876-84.10.4049/jimmunol.1103227340234222711893
Search in Google Scholar Back to article
36. Riley JL. PD-1 signaling in primary T cells. Immunol Rev. 2009; 229: 114-125.10.1111/j.1600-065X.2009.00767.x342406619426218
Search in Google Scholar Back to article
37. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A. 2001; 98: 13866-13871.10.1073/pnas.2314865986113311698646
Search in Google Scholar Back to article
38. Schlößer HA, Theurich S, Shimabukuro-Vornhagen A, Holtick U, Stippel DL, von Bergwelt-Baildon M. Overcoming tumor-mediated immunosuppression. Immunotherapy., 2014; 6: 973-98810.2217/imt.14.58
Search in Google Scholar Back to article
39. Chen X et al. PD-1 regulates extrathymic regulatory T-cell differentiation. Eur J Immunol. 2014; 44: 2603-2616.10.1002/eji.201344423416570124975127
Search in Google Scholar Back to article
40. Meng Y, Liang H, Hu J, Liu S, Hao X, Wong MSK, Li X, Hu L. PD-L1 Expression Correlates With Tumor Infiltrating Lymphocytes And Response To Neoadjuvant Chemotherapy In Cervical Cancer. J Cancer. 2018;9(16):2938-2945.10.7150/jca.22532609636430123362
Search in Google Scholar Back to article
41. Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol. 2016;27(8):1492-504.10.1093/annonc/mdw21727207108
Search in Google Scholar Back to article
42. Taube JM et al. Colocalization o inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012 28;4(127):12710.1126/scitranslmed.3003689356852322461641
Search in Google Scholar Back to article
43. Cheng B, Yuan WE, Su J, Liu Y, Chen J. Recent advances in small molecule based cancer immunotherapy. Eur J Med Chem. 2018;157:582-598.10.1016/j.ejmech.2018.08.02830125720
Search in Google Scholar Back to article
44. Ostrand-Rosenberg S, Horn LA, Haile ST. The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. J Immunol. 2014 Oct 15;193(8):3835-41.10.4049/jimmunol.1401572418542525281753
Search in Google Scholar Back to article
45. Larkin J et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(13): 1270-1.10.1056/NEJMc150966026398076
Search in Google Scholar Back to article
46. Roger A et al. Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients. Oncoimmunology. 2018;7(7): e1442166.10.1080/2162402X.2018.1442166605330030034949
Search in Google Scholar Back to article
47. Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, Durham N, Meyer C, Harris TJ, Albesiano E, Pradilla G, Ford E, Wong J, Hammers HJ, Mathios D, Tyler B, Brem H, Tran PT, Pardoll D, Drake CG, Lim M. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86(2):343-9.2346241910.1016/j.ijrobp.2012.12.025396340323462419
Open DOI Search in Google Scholar Back to article
48. Choi N, Shin DY, Kim HJ, Moon UY, Baek KH, Jeong HS. Postoperative anti-PD-1 antibody treatment to reduce recurrence in a cancer ablation surgical wound. J Surg Res. 2018;221:95-103.10.1016/j.jss.2017.08.02229229160
Search in Google Scholar Back to article
49. Qin L et al. Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia. Oncotarget. 2016;7(38):61069-61080.10.18632/oncotarget.11179530863627517629
Search in Google Scholar Back to article
50. Blankenstein T, Coulie PG, Gilboa E, Jaffee EM. The determinants of tumour immunogenicity. Nat Rev Cancer. 2012 1;12(4):307-13.10.1038/nrc3246355260922378190
Open DOI Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.2478/sjecr-2018-0033 | Journal eISSN: 2956-2090 | Journal ISSN: 2956-0454

Journal RSS Feed

Language: English

Page range: 223 - 228

Submitted on: Aug 31, 2018

Accepted on: Sep 4, 2018

Published on: Nov 7, 2019

Published by: University of Kragujevac, Faculty of Medical Sciences

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

IL-33,

PD-1,

tumor,

antitumor immunity

Related subjects:

Medicine,

Clinical medicine,

Clinical medicine, other

© 2019 Marina Jovanovic, Nevena Gajovic, Miodrag L. Lukic, Ana Popovic, Ivan Jovanovic, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 20 (2019): Issue 3 (September 2019)